Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Retained Earnings (2016 - 2025)

Avanos Medical (AVNS) has disclosed Retained Earnings for 13 consecutive years, with -$779.9 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 10.31% to -$779.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$779.9 million through Dec 2025, down 10.31% year-over-year, with the annual reading at -$779.9 million for FY2025, 10.31% down from the prior year.
  • Retained Earnings hit -$779.9 million in Q4 2025 for Avanos Medical, roughly flat from -$778.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$30.0 million in Q2 2021 to a low of -$779.9 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$276.5 million across 5 years, with a median of -$301.4 million in 2022.
  • Biggest YoY gain for Retained Earnings was 90.06% in 2022; the steepest drop was 877.0% in 2022.
  • Year by year, Retained Earnings stood at -$33.8 million in 2021, then tumbled by 648.82% to -$253.1 million in 2022, then decreased by 24.42% to -$314.9 million in 2023, then crashed by 124.52% to -$707.0 million in 2024, then decreased by 10.31% to -$779.9 million in 2025.
  • Business Quant data shows Retained Earnings for AVNS at -$779.9 million in Q4 2025, -$778.6 million in Q3 2025, and -$32.0 million in Q2 2025.